Description
The Bone Resorption Assessment is a simple urinary test that provides an accurate assessment of an individual’s rate of bone turnover. The Bone Resorption Assessment enables practitioners to identify individuals at a higher risk of developing osteoporosis, intervene before significant loss has occurred, and monitor the efficacy of treatment regimens. It examines pyridinium crosslinks and deoxypyridinoline, which help identify the current rate of bone loss, lytic bone disease, and the efficacy of bone support therapies.
Hormone Testing and Osteoporosis:
- Osteoporosis leads to 1.5 million fractures per year
- Osteoporosis affects more than 50% of healthy American women aged 30-40, who are likely to develop vertebral fractures as they age
- Hormone testing is an important component to identify individuals currently losing bone at an accelerated rate so that effective treatment can begin before significant bone loss has occurred
Measuring Bone Resorption
Pyridinium crosslinks are stabilisers of collagen molecules. Bone collagen contains bothpyridinoline (PYD), which is reflective of collagen loss of all types, and its component deoxypyridinoline (DPD), which specifically reflects bone collagen. The presence in the urine of higher-than-normal amounts of PYD and DPD indicates a rapid rate of bone loss.
Crosslink excretion is greatly increased in patients with osteoporosis, as well as in a number of other conditions. These include Paget’s disease, primary hyperparathyroidism, and osteomalacia. Measurement of PYD crosslinks has also proven useful in arthritic diseases, connective tissue disorders, cancer metastasis, and alcoholic bone disease.
Test Type:
Urine Test
